American Society of Hematology, Blood Advances, 23(3), p. 3962-3967, 2019
DOI: 10.1182/bloodadvances.2019000731
Full text: Download
Key Points Leukemia-associated mutations can be detected many years before the onset of secondary leukemias in myeloma patients. Stem and progenitor cells can act as reservoirs of mutations before the onset of secondary MDS and AML after treatment of myeloma.